Scripps Health is expanding facilities, investing in its workforce and earning national quality recognition. Yet its leadership says the system is preparing for more than $100 million in annual financial exposure beginning around 2027.

For Scripps-affiliated physicians, the key question is not whether that pressure eventually appears on a balance sheet. It is what changes first if revenue growth slows while labor, drugs, supplies and new clinical technologies continue getting more expensive.

The warning is not new.

CEO Chris Van Gorder has argued for more than a year that hospital economics are becoming harder to sustain as government reimbursement and coverage pressures increase. In May 2025, he warned that hospital finances were becoming increasingly fragile as Medicare and Medicaid payments failed to keep pace with care costs.

Scripps has also shown that it will act when leadership concludes a payer relationship is no longer sustainable.

The system exited nearly all of its commercial Medicare Advantage contracts in 2024. Van Gorder later said those contracts covered about 32,000 beneficiaries and were costing Scripps roughly $75 million a year. He cited not only reimbursement, but also prior authorization and disputes over payments Scripps believed it was contractually owed.

That history makes the current forecast more consequential.

Scripps says its projected $100 million-plus annual exposure combines several separate pressures, including federal Medicaid-related changes, uncertainty around California provider-fee revenue, the expiration of enhanced ACA Marketplace subsidies and possible 340B-related changes. The figure is a Scripps projection, not a realized loss.

The financial pressure also may not fall evenly across the system.

In a January 2026 interview, Van Gorder and CFO Brett Tande said hospitals serving larger Medi-Cal populations would face greater exposure. Van Gorder cited Scripps Chula Vista, which he said is operating at about a $40 million annual loss that the broader system currently absorbs.

At the same time, California is requiring healthcare spending growth to slow.

The statewide per-capita healthcare spending-growth target is 3.5% in 2026, falling to 3.2% in 2027 and 2028 and 3% in 2029. The state is not imposing a fixed hospital budget. Rather, it is setting targets for the rate at which healthcare spending can grow.

The 2026 performance year is the first that can ultimately lead to enforcement, although any resulting action would come later.

That creates the central tension.

Van Gorder argues that hospitals cannot fully control major cost drivers such as labor, pharmaceuticals, supplies, and medical technology. Yet those are also areas closely tied to patient care and clinical innovation.

Scripps has historically tried to protect its workforce. Van Gorder has repeatedly emphasized reducing waste, standardizing care and renegotiating contracts before cutting employees. Even amid the current forecast, he has said Scripps intends to protect staff as long as possible.

That makes workforce changes an important indicator for physicians.

If efficiencies, payer negotiations and cross-subsidization prove insufficient, physicians would likely watch for pressure on staffing, appointment capacity, service-line expansion, technology investment and capital projects.

Van Gorder has already acknowledged that service adjustments could become necessary if the projected financial pressure materializes, although Scripps has not identified specific programs for reduction.

For now, Scripps remains operationally strong and reported a positive 6.6% operating margin in the second quarter of 2026, although the timing of California provider-fee revenue materially boosted those results.

The harder test begins if projected federal revenue pressure arrives as California requires progressively slower spending growth.

For physicians, the practical question is straightforward: if those pressures converge, what gets protected first—and what becomes harder to sustain?

Scripps has not publicly detailed exactly how much of the projected $100 million exposure comes from each federal or state policy change, whether it expects to exceed California’s spending-growth target, or which clinical programs would be protected or reconsidered if the forecasted pressure materializes.